Merck & Company Inc (MRK)vsRenovoRx Inc (RNXT)
MRK
Merck & Company Inc
$146.35
+3.85%
HEALTHCARE · Cap: $360.08B
RNXT
RenovoRx Inc
$1.43
+2.52%
HEALTHCARE · Cap: $58.22M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3368776% more annual revenue ($66.57B vs $1.98M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
RNXT
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Intrinsic value data unavailable for RNXT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Revenue surging 115.4% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RNXT
The strongest argument for RNXT centers on Revenue Growth, Debt/Equity. Revenue growth of 115.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RNXT
The primary concerns for RNXT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while RNXT is a hypergrowth play — different risk/reward profiles.
RNXT carries more volatility with a beta of 0.97 — expect wider price swings.
RNXT is growing revenue faster at 115.4% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →RenovoRx Inc
HEALTHCARE · BIOTECHNOLOGY · USA
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. The company is headquartered in Los Altos, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?